Optum study shows BLC and WLC have equivalent real-world costs in non-muscle-invasive bladder cancer care
Executive summary: Optum published a real-world U.S. study showing cost neutrality between blue light cystoscopy (BLC) and white light cystoscopy (WLC) in non-muscle-invasive bladder cancer care. The finding addresses a key barrier to BLC adoption — perceived higher costs — by demonstrating equivalent total healthcare spending, supporting broader clinical use.
Who is involved: Photocure ASA (OSE: PHO), Optum, and U.S. healthcare providers analyzing retrospective claims and clinical data.
Likely next: Increased reimbursement discussions and potential inclusion of BLC in clinical guidelines as a cost-effective diagnostic option.
A new retrospective analysis by Optum finds no significant difference in healthcare resource utilization or costs between blue light cystoscopy (BLC) and white light cystoscopy (WLC) for diagnosing and managing non-muscle-invasive bladder cancer in a U.S. real-world setting. The study, published by Photocure ASA, evaluates total healthcare expenditures including procedures, imaging, and follow-up care. Results suggest BLC, despite higher upfront technology costs, does not increase overall system burden when used in routine clinical practice. This supports prior clinical evidence that BLC improves detection without raising net costs.
What's next — scenarios
Cost Neutrality Validation (Base Case) (60%)
Healthcare providers adopt BLC more aggressively as the 'value-based care' argument removes budget friction.
- Widespread inclusion of BLC in standard clinical guidelines
- Stabilization of reimbursement rates for BLC procedures
Technology Scaling & Margin Expansion (Upside) (25%)
Manufacturers of BLC technology capture increased market share without triggering payer pushback.
- Volume-based price reductions in BLC hardware
- Expansion of BLC use into broader uro-oncology segments
Payer Resistance/Reimbursement Friction (Downside) (15%)
Despite the Optum study, administrative hurdles or narrow coverage lists limit BLC growth.
- New restrictive prior authorization requirements for BLC
- Insurance providers decoupling BLC from standard WLC reimbursement bundles
What to watch
- CMS reimbursement updates for cystoscopy-related codes (next 60 days)
- Quarterly earnings reports from Photocure ASA regarding US market penetration (next 90 days)
- Peer-reviewed follow-up studies on long-term recurrence reduction vs. cost (next 90 days)
Timeline
- — Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. (PR Newswire)
Analysis — what this means
Likely next events
- Photocure may seek expanded CPT coding or reimbursement review by CMS in Q1 2027 based on cost-neutrality evidence
- European urology associations may update guidelines by mid-2027 to reflect real-world U.S. data on BLC cost equivalence
Sectors affected
- Medical device diagnostics
- Urology healthcare services
- Bladder cancer screening and surveillance
Regulatory implications
- FDA may consider real-world evidence like this study in future premarket or post-market assessments for BLC technologies
Historical parallels
- Similar cost-neutrality argument used for da Vinci robotic surgery adoption in prostatectomy circa 2010–2015
- MRI-guided biopsy uptake in prostate cancer faced early cost concerns but gained traction after long-term savings data emerged (~2018)
Key entities
Sources
- Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. — PR Newswire